advanced enzymes
Where ENZYME is Life

Advanced Enzyme Technologies Ltd.
CIN: L24200MH1989PLC051018
Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)-400 604, India
Tel: +91-22-4170 3200, Fax: +91-22-2583 5159
Email: info@advancedenzymes.com, www.advancedenzymes.com

August 08, 2026

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai- 400 001

Scrip Code-540025

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (E) Mumbai- 400 051

Trading Symbol-ADVENZYMES

Subject: Press Release
Ref: ISIN: INE837H01020

Dear Sir/Madam,

Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release" dated August 08, 2026.

This is for your information and for public at large.

Thanking you,
Yours faithfully,
For Advanced Enzyme Technologies Limited

SANJAY PRAKASH BASANTANI
Digitally signed by SANJAY PRAKASH BASANTANI
Date: 2026.08.08 16:04:50 +05'30'

Sanjay Basantani
Company Secretary and Head – Legal

Encl.: As above

FOR IMMEDIATE RELEASE

QUARTERLY EARNINGS RELEASE

Thane, India: Saturday, August 08, 2026

Advanced Enzyme Technologies Limited announces Financial Results for First Quarter ended June 2026

Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading specialty biotech company, with global leadership in the manufacturing of enzymes, today announced their unaudited financial results for first quarter ended June 2026.

CONSOLIDATED QUARTERLY FINANCIAL HIGHLIGHTS:

(Amount in INR Mn.)	Q1 FY27	Q4 FY26	Q1 FY26	Change (Y-o-Y %)	Change (Q-o-Q %)	FY26	FY25	Change (%)
Revenue	1,898	2,034	1,859	+2%	-7%	7,458	6,369	+17%
EBITDA	510	632	564	-10%	-19%	2,291	1,944	+18%
EBITDA Margin (%)	27%	31%	30%			31%	31%	
PAT	386	453	404	-5%	-15%	1,736	1,340	+30%
PAT Margin (%)	20%	22%	22%			23%	21%	
EPS	3.31	3.84	3.57	-7%	-14%	15.08	11.72	+29%

CONSOLIDATED FINANCIAL REVIEW (Y-o-Y basis):

Revenue from Operations:
Revenue from operations on consolidated basis increased to ₹ 1,898 million in Q1 FY27 from ₹ 1,859 million in Q1 FY26, a growth of 2%.

Profit:
Consolidated EBITDA during Q1 FY27 stands at ₹ 510 million as compared to ₹ 564 million during Q1 FY26, decreased by 10%.

Profit before tax stands at ₹ 535 million during Q1 FY27 as against ₹ 549 million in Q1 FY26, decreased by 3%.

Profit after tax de-grew by 5% and stands at ₹ 386 million during Q1 FY27 as compared to ₹ 404 million during Q1 FY26.

Margin:
EBITDA margin stands at 27%, PBT margin stands at 28% and PAT margin stands at 20% during the quarter.

Financial Costs:
Financial costs stood at ₹ 6 million during Q1 FY27 as against ₹ 8 million in Q1 FY26.

Depreciation and Amortization:
Depreciation and Amortization charge for Q1 FY27 stood at ₹ 99 million as compared to ₹ 96 million in the same quarter previous year.

Earnings Per Share:
Earnings Per Share during Q1 FY27 stands at ₹ 3.31 as compared to ₹ 3.57 in Q1 FY26.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q1 FY27	Q1 FY26	Change (%)
Human Nutrition	1,139	1,221	-7%
Animal Nutrition	252	260	-3%
Bio-Processing	306	236	+30%
Specialized Manufacturing	200	142	+41%



The total revenue from operations grew by 2% on y-o-y basis and de-grew by 7% on q-o-q basis.

Revenue from the Human Nutrition segment declined by 7% y-o-y to ₹1,139 million in Q1 FY27, compared with ₹1,221 million in Q1 FY26. The decline was primarily attributable to lower sales in the Pharma/API business.

The Animal Nutrition segment reported a 3% y-o-y decline in revenue to ₹252 million in Q1 FY27, compared with ₹260 million in Q1 FY26.

The Bio-Processing segment delivered a strong performance during the quarter, with revenue increasing by 30% year-on-year to ₹306 million in Q1 FY27 from ₹236 million in Q1 FY26. Within the segment, the Food business registered robust growth of 51% y-o-y, reaching ₹263 million in Q1 FY27. In contrast, the Non-Food business declined by 30% y-o-y to ₹43 million during the quarter.

The Specialized Manufacturing segment contributed 11% to the Company's total revenue during the quarter, with revenue increasing by 41% y-o-y to ₹200 million.

Geographical Revenue:



Domestic sales accounted for ₹ 937 million in Q1 FY27 as compared to ₹ 979 million in Q1 FY26, lower by 4%.

The total revenue comprises of International sales amounting to ₹ 961 million in Q1 FY27 as compared to ₹ 881 million in Q1 FY26, an increase of 9%. The revenue declined by 3% in Americas and 15% in the rest of the world while registered a growth of 44% in Europe, 37% in Asia (ex-India).

The domestic sales constituted about 49% of revenue from operations during Q1 FY27 as compared to 53% during Q1 FY26. International sales were 51% of revenue from operations during Q1 FY27 as compared to 47% during Q1 FY26.

CONSOLIDATED FINANCIAL REVIEW (Q-o-Q basis):

Revenue from Operations:
Revenue from operations on consolidated basis decreased to ₹ 1,898 million in Q1 FY27 from ₹ 2,034 million in Q4 FY26, a de-growth of 7%.

Profit:
Consolidated EBITDA during Q1 FY27 stands at ₹ 510 million as compared to ₹ 632 million during Q4 FY26, lower by 19%.

Profit before tax stands at ₹ 535 million during Q1 FY27 as against ₹ 598 million in Q4 FY26, decreased by 10%

Profit after tax de-grew by 15% and stands at ₹ 386 million during Q1 FY27 as compared to ₹ 453 million during Q4 FY26.

Financial Costs:
Financial costs remain unchanged and stood at ₹ 6 million during Q1 FY27 as compared to last quarter.

Depreciation and Amortization:
Depreciation and Amortization charge for Q1 FY27 is ₹ 99 million as compared to ₹ 102 million in the last quarter.

Earnings Per Share:
Earnings Per Share during Q1 FY27 stands at ₹ 3.31 as compared to ₹ 3.84 in Q4 FY26.

OPERATIONAL PERFORMANCE REVIEW:

Segmental Revenue:

(Amount in INR Mn.)	Q1 FY27	Q4 FY26	Change (%)
Human Nutrition	1,139	1,281	-11%
Animal Nutrition	252	250	+1%
Bio-Processing	306	324	-5%
Specialized Manufacturing	200	180	+11%

The human nutrition segment reflected a de-growth 11% to ₹ 1,139 million in Q1 FY27 as compared to ₹ 1,281 million in Q4 FY26.

The Animal nutrition grew by 1% to ₹ 252 million in Q1 FY27 as against ₹ 250 million in Q4 FY26.

The Bio-Processing segment recorded a 5% quarter-on-quarter decline in revenue to ₹306 million in Q1 FY27 from ₹324 million in Q4 FY26. Within the segment, the Food business declined by 5% quarter-on-quarter to ₹263 million, while the Non-Food business registered an 8% q-o-q decrease to ₹43 million.

The Specialized manufacturing segment registered a growth of 11% to ₹ 200 million in Q1 FY27 from ₹ 180 million in Q4 FY26.

Geographical Revenue:

Domestic sales accounted for ₹ 937 million in Q1 FY26 as compared to ₹ 1,061 million in Q4 FY26, a de-growth of 12%. The domestic sales constituted about 49% of revenue from operations during Q1 FY27 as compared to 52% during Q4 FY26.

The total revenue comprises of International sales amounting to ₹ 961 million in Q1 FY27 as compared to ₹ 973 million in Q4 FY26, marginal decline of 1%. The revenue de-grew by 5% in Americas, 3% in Asia (ex-India) and 29% in rest of the world while registered a growth of 39% in Europe.

International sales were 51% of revenue from operations during Q1 FY27 as compared to 48% during Q4 FY26.

OUTLOOK 2026-27

Advanced Enzymes remains committed to enhancing and strengthening its business model by maintaining a strong focus across its three key segments—Human Nutrition, Animal Nutrition, and Bio-Processing. The company is actively working on expanding its product portfolio, particularly in the probiotics space, through ongoing development and new product launches. With its current infrastructure and capital investments, Advanced Enzymes is well-positioned to grow its enzymes and probiotics business.

Human Nutrition:

The Company already operates a successful B2C business in the USA and is now replicating this model in India to drive growth and explore new opportunities. It remains committed to expanding its B2C presence within the Human Nutrition sector. As part of this strategy, the Company has launched its own nutraceutical brand, Wellfa, targeting to Indian consumers. The brand offers a wide range of products, including immune support, skincare, gut health, metabolism enhancement, detox solutions, weight management, stress relief, and respiratory health, among others.

This segment is expected to become a key growth driver for the Company. Additionally, it is selling through other online platforms to diversify and strengthen its digital sales channels.

Animal Nutrition:

In the Animal Nutrition segment, the Company is actively carrying out trials and research to develop innovative and more effective nutritional products aimed at enhancing the performance of animal feeds. Efforts are underway to register and launch additional products in both domestic and international markets. Simultaneously, the Company plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while also aiming to broaden its global presence by appointing new distributors in international markets.

Probiotics:

The Company continuously make efforts on introducing additional probiotic products in the Human Nutrition segment, focusing on immunity enhancement, active health foods, gut health, and various nutraceutical applications. In the Animal Nutrition segment, it is committed to launching new products aimed at boosting immunity, improving digestion, and enhancing the nutritional value of animal feed.

Bio Catalysis:

The Company has achieved notable progress in developing biocatalysis for API manufacturers, offering targeted enzymatic solutions that help reduce energy consumption, processing time, and chemical usage. Some of these products are at various stages of development, with a few currently in advanced plant-level trials with API manufacturers. This area represents a key opportunity where the Company intends to maintain its focus and ongoing efforts.

Baking:

The Company offers a diverse portfolio of enzymes for the food processing sector and has submitted 15 dossiers to the European Food Safety Authority (EFSA), receiving positive opinions for 9 of them. Its product range demonstrates efficacy and performance on par with leading industry players. With a strong focus on value-driven solutions, the Company is well-positioned to expand its presence across Europe, the Americas, and other global markets, particularly within the baking industry.

Research & Development:

The Company is making substantial investments in state-of-the-art R&D infrastructure, aiming to lead innovation in the formulation of new applications. With a strong focus on expanding its application portfolio across various industries, the Company remains committed to ongoing R&D investment. It also plans to further strengthen its R&D team to support this growth and drive future advancements.

Inorganic expansion:

The Company has a strong track record of inorganic growth, having successfully completed four acquisitions over the past nine years, all financed through internal accruals, maintaining its status as a zero-debt entity. It will continue to explore strategic acquisition opportunities that can enhance its front-end marketing capabilities, expand its geographical footprint, strengthen its product portfolio, and bolster its B2C business.

RESULTS CONFERENCE CALL DETAILS

Advanced Enzymes will hold an earnings conference call on 12th August 2026, Wednesday at 16:00 Hours IST to discuss quarterly performance. The transcript of the call will be available later in the Investor Relations section on the Company's website, www.advancedenzymes.com

Please dial the numbers at least 5-10 minutes prior to the conference schedule to ensure that you are connected on time.

Conference Call Primary Number: +91 86 3416 8438 / +91 86 4536 6489

Pre-registration link

For further information, please contact:

Ronak Saraf
Investor Relations
ir@advancedenzymes.com

CORPORATE INFORMATION:
Advanced Enzyme Technologies Limited
Regd. Office: 5th Floor, 'A' Wing, Sun Magnetica,
Louiswadi, Thane (W) -400 604,
Maharashtra, India
Tel.: +91 22 41703200
Fax: +91-22 25835159
Website: www.advancedenzymes.com
CIN No: L24200MH1989PLC051018